Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13), Zacks reports.
Unicycive Therapeutics Stock Down 2.0 %
Unicycive Therapeutics stock opened at $0.61 on Monday. The firm has a fifty day simple moving average of $0.59 and a two-hundred day simple moving average of $0.57. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.60. The company has a market capitalization of $63.73 million, a PE ratio of -0.63 and a beta of 2.26.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Unicycive Therapeutics in a research note on Wednesday, January 29th.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Featured Articles
- Five stocks we like better than Unicycive Therapeutics
- What to Know About Investing in Penny Stocks
- Lululemon Pulls Back Into Classic Dip-Buying Opportunity
- What is a support level?
- Cintas Delivers Earnings Beat, Signals More Growth Ahead
- Best Stocks Under $10.00
- Analysts Say These 4 Low P/E Consumer Cyclical Stocks Are Buys
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
